Biomarker testing in ovarian cancer to guide future treatment
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study looks at tumor tissue from ovarian cancer patients to find “biomarkers,” or lab signals, that may predict how the disease behaves or how it might respond to treatment. You may be asked for a biopsy of the relapsed (coming back) tumor or to use an existing archived tumor sample.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have ovarian cancer (new diagnosis or relapsed after prior treatment)
- If your cancer is relapsed, your study site must be able to access stored primary tumor tissue or obtain new tissue from a relapsed spot
- You may need a CT-guided biopsy of the relapse, or a tissue sample during surgery for relapse
- You must sign informed consent before any study steps
- You must be age 18 or older
- You need to be covered by a social security health plan (or be a covered beneficiary)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new blood test that may help detect ovarian cancer earlier. Researchers want to see if it can tell the difference between people with ovarian cancer and those without it.
This study aims to use your tumor and blood samples to find the best treatment for your ovarian cancer. It may help tailor your care based on your unique cancer biology.
This study is testing a blood test to see if it can catch ovarian cancer early. You may be eligible if you have been recently diagnosed with ovarian cancer and haven't started treatment yet.
This study uses a custom lab test on blood (and tumor tissue) to track ovarian cancer returning and to see how well treatment is working. It may help your care team monitor changes over time, especially after certain surgeries.
This study looks for cancer DNA in your blood to understand advanced ovarian cancer better. It helps doctors see how the disease changes over time and may improve future treatments.
This study looks at certain substances in the body (called metabolic biomarkers) and how they relate to how well patients do after treatment. It is for women who have just been diagnosed with high-grade serous ovarian cancer and have not yet had any treatment.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.